Enhancing Donated After Cardiac Death (DCD) Utilization With Thrombolytic Therapy
| Status: | Completed |
|---|---|
| Conditions: | Renal Impairment / Chronic Kidney Disease |
| Therapuetic Areas: | Nephrology / Urology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 8/30/2018 |
| Start Date: | April 2010 |
| End Date: | May 2018 |
Enhancing DCD Utilization With Thrombolytic Therapy
We hypothesize that delayed graft function and ITBS events may be related to small blood
clots (microthrombi) that collect in the kidneys and liver after cardiac death. Treatment of
the DCD organs with a thrombolytic agent prior to implantation may reduce post-transplant
morbidity and mortality, and may ultimately result in a greater number of transplantable
livers and kidneys.
clots (microthrombi) that collect in the kidneys and liver after cardiac death. Treatment of
the DCD organs with a thrombolytic agent prior to implantation may reduce post-transplant
morbidity and mortality, and may ultimately result in a greater number of transplantable
livers and kidneys.
The waiting list for kidney and liver transplantation continues to increase in the United
States, and therefore the need grows for additional donor organs. Utilization of organs
donated after cardiac death (DCD) could be one way to increase organ availability, however
there are risks associated with poorer clinical outcomes, including delayed graft function
and in livers specifically, ischemic-type biliary strictures (ITBS). We hypothesize that
delayed graft function and ITBS events may be related to small blood clots (microthrombi)
that collect in the kidneys and liver after cardiac death. Treatment of the DCD organs with a
thrombolytic agent prior to implantation may reduce post-transplant morbidity and mortality,
and may ultimately result in a greater number of transplantable livers and kidneys.
States, and therefore the need grows for additional donor organs. Utilization of organs
donated after cardiac death (DCD) could be one way to increase organ availability, however
there are risks associated with poorer clinical outcomes, including delayed graft function
and in livers specifically, ischemic-type biliary strictures (ITBS). We hypothesize that
delayed graft function and ITBS events may be related to small blood clots (microthrombi)
that collect in the kidneys and liver after cardiac death. Treatment of the DCD organs with a
thrombolytic agent prior to implantation may reduce post-transplant morbidity and mortality,
and may ultimately result in a greater number of transplantable livers and kidneys.
Inclusion Criteria:
- Adults aged 18 years and older
- Subjects willing/able to provide written consent
- Subjects willing/able to comply with study requirements
- Subjects who will receive a solitary organ transplant
Exclusion Criteria:
- Subjects requiring multi-organ transplants
- Women who are pregnant
- Subjects with current severe systemic infection
- Subjects with an active infection
We found this trial at
2
sites
Click here to add this to my saved trials
Cleveland Clinic Cleveland Clinic is committed to principles as presented in the United Nations Global...
Click here to add this to my saved trials